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Abstract. 
 
STAT transcription factors are induced by a 
number of growth factors and cytokines. Within min-
utes of induction, the STAT proteins are phosphory-
lated on tyrosine and serine residues and translocated 
to the nucleus, where they bind to their DNA targets. 
The leukemia inhibitory factor (LIF) mediates pleio-
tropic and sometimes opposite effects both in vivo and 
in cultured cells. It is known, for example, to prevent 
differentiation of embryonic stem (ES) cells in vitro. To 
get insights into LIF-regulated signaling in ES cells, we 
have analyzed protein-binding and transcriptional 
properties of STAT recognition sites in ES cells culti-
vated in the presence and in the absence of LIF. We 
have detected a specific LIF-regulated DNA-binding 
activity implicating the STAT3 protein. We show that 
STAT3 phosphorylation is essential for this LIF-depen-
dent DNA-binding activity. The possibility that ERK2 
or a closely related protein kinase, whose activity is 
modulated in a LIF-dependent manner, contributes to 
this phosphorylation is discussed. Finally, we show that 
the multimerized STAT3-binding DNA element con-
fers LIF responsiveness to a minimal thymidine kinase 
promoter. This, together with our observation that 
overexpression of STAT3 dominant-negative mutants 
abrogates this LIF responsiveness, clearly indicates that 
STAT3 is involved in LIF-regulated transcriptional 
events in ES cells. Finally, stable expression of such a 
dominant negative mutant of STAT3 induces morpho-
logical differentiation of ES cells despite continuous 
LIF supply. Our results suggest that STAT3 is a critical 
target of the LIF signaling pathway, which maintains 
pluripotent cell proliferation.
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1. 
 
Abbreviations used in this paper
 
: CAT, chloramphenicol acetyl trans-
ferase; ES, embryonic stem (cells); HA, hemagglutinin; LIF, leukemia in-
hibitory factor; MAP, mitogen-activated protein; TK, thymidine kinase.
 
T
 
he 
 
IL-6 cytokine family, including IL-6, leukemia
inhibitory factor (LIF)
 
1
 
, ciliary neurotrophic factor,
oncostatin M, and cardiotrophin-1, has wide pleio-
tropic effects on cell growth and differentiation. Signaling
by these cytokines is transduced by activation of compos-
ite receptors that share the common gp130 subunit (26, 28,
40, 56). The structural diversity of these receptors and the
cell type–dependent variability of expression of their sub-
units account, at least in part, for the specific and redun-
dant functions of this class of hormones (11, 34, 52) . Char-
acterization of the effectors of these cell signaling molecules
is an essential step towards the elucidation of the mecha-
nisms underlying the pleiotropic effects they mediate.
The gp130 protein and the LIF receptor 
 
b
 
 (LIFR
 
b
 
) con-
stitutively interact with the Jak1 and Jak2 tyrosine kinases.
Activation of these kinases occurs as a result of LIF-
induced dimerization of the receptor components (gp130-
LIFR
 
b
 
) and leads to their phosphorylation (22, 31, 34, 52,
53). Transcription factors from the STAT family can also
be phosphorylated and recruited by the receptor, as shown
in HepG2 cells treated with IL-6 (34). Different combina-
tions of Jak kinases and STAT transcription factors are ac-
tivated, depending on both the ligand and cell line (52).
The members of the STAT family of transcription factors
have first been described as effectors in the IFN-
 
a
 
/
 
b
 
 and
IFN-
 
g
 
 signaling pathways (25, 50). These dual-function
factors, which contain SH2 and SH3 domains as well as a
DNA-binding domain, are activated by growth factors
(such as EGF and PDGF) and by cytokines (20, 50, 51).
The STAT proteins are regulated by tyrosine and serine
phosphorylation, a necessary step for dimerization, nu-
clear translocation, DNA-binding, and transcriptional ac-
tivation (27, 59, 60). Tyrosine kinases of the Jak and of the
Src families, as well as serine/threonine kinases of the mi-
togen-activated protein (MAP) kinase family, have been
involved in STAT regulation (7, 13, 14, 62, 64). The
STAT3 transcription factor, originally cloned as an EGF-
and IL-6–induced transcription factor, is activated in many
cell types by a broad range of cytokines (1, 5, 12, 65). A
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natural truncated form of STAT3, named STAT3
 
b
 
, be-
haves as a constitutive transcription factor whose activity
is synergized by association with Jun (48).
LIF plays a crucial role in vivo during preimplantation
of mammalian embryos and is essential for the mainte-
nance of the pool of hematopoietic stem cells (16, 54). An-
tagonistic effects of LIF on cultured cell lines are also well
established: LIF inhibits differentiation of embryonic stem
(ES) cells and, on the contrary, induces differentiation of
other cell lines, such as the M1 myeloid cell line, the MAH
sympathoadrenal progenitor cells, and the NBFL neuro-
blastoma cell line (6, 21, 29). LIF is also a potent activator
of myoblast proliferation (36). Ciliary neurotrophic factor
and oncostatin M also have the property to maintain the
pluripotentiality of ES cells in vitro (9, 41, 43).
Characterization of the effectors of LIF in ES cells may
provide insights into the mechanisms leading to early dif-
ferentiation events in vitro. Thus, it would be of interest to
determine whether similar proteins can be activated by
LIF in cell lines in which this cytokine has opposite effects.
The STAT3 transcription factor, which is phosphorylated
on tyrosine upon LIF treatment in M1 myeloid cells, is
also activated in ES cells maintained in the presence of
LIF, but its specific effect on cell differentiation in ES cells
has not been addressed (1, 23). It has been shown recently,
however, that STAT3 is a critical factor involved in IL-6–
and LIF-dependent differentiation of the M1 myeloid cell
line (37, 38). Activation of MAP kinases by LIF has been
reported, but its biological significance is yet unknown (15,
49, 61). Also, it has been shown that the low affinity LIF
receptor subunit can be phosphorylated in vitro by the
ERK2 serine/threonine kinase in the preadipocyte 3T3-L1
cell line. Phosphorylation of the LIF receptor, however, is
not crucial for LIF signaling in these cells (49).
In this study, we demonstrate that the SIE DNA-bind-
ing site of the c-
 
fos
 
 promoter, which is a target for STAT1/
STAT3 in EGF-treated cells (17, 65), is specifically bound
by a STAT3-containing protein in ES cells maintained in
the presence of LIF. We examine the expression and phos-
phorylation of the STAT3 protein in these cells in re-
sponse to LIF treatment or withdrawal. We show that the
c-
 
fos
 
 promoter is LIF responsive in ES cells, and that the
multimerized SIE element confers LIF-dependent tran-
scription to the minimal TK promoter. We demonstrate
that STAT3 mutants, which behave as dominant negative
factors in the IL-6 pathway (38), can repress LIF-depen-
dent transcription. We also show that stable expression of
one of these mutants (STAT3F) leads to morphological
differentiation of the ES cells. Finally, we present evi-
dence that the ERK2 serine/threonine kinase is involved
in the primary LIF response in ES cells.
 
Materials and Methods
 
Cells and Extracts
 
Embryonic cell lines were derived from the inner cell mass of mouse blas-
tocysts as described (42). The cells were grown at 37
 
8
 
C, under 7% CO
 
2
 
, on
gelatinized plates in DME supplemented with 15% FCS, 0.1 mM 
 
b
 
-mer-
captoethanol, and 1 mM sodium pyruvate. Recombinant murine LIF
(
 
z
 
1,000 U/ml) was added when appropriate. Where indicated, the cells
were treated with 100 nM Staurosporine (Sigma Chemical Co., St. Louis,
MO), 27 
 
m
 
g/ml Genistein, or 1 
 
m
 
g/ml Herbimycin A (BIOMOL Research
Laboratories, Plymouth Meeting, PA) for 20 h. Cytosolic and nuclear ex-
tracts were prepared as described (44).
 
Electrophoretic Band-Shift Assay
 
Gel retardation experiments were carried out in 20 
 
m
 
l final volume as de-
scribed (44): 3 
 
m
 
g of nuclear extract was incubated with 1 
 
m
 
g of poly dI/dC
for 10 min at 4
 
8
 
C; competitor oligonucleotides (100-fold molar excess with
respect to probe) were added and further incubated for 10 min at 4
 
8
 
C. The
 
32
 
P 5
 
9
 
 end-labeled probe (
 
z
 
10,000 cpm, 5 fmol per reaction) was then
added, and the mixture was incubated at 25
 
8
 
C for 15 min. The reactions
were loaded on nondenaturing 4.5% polyacrylamide gels. After electro-
phoresis, the gels were dried and exposed for autoradiography.
For supershift experiments, nuclear lysates were preincubated with
specific antibodies (see above): 1 
 
m
 
g of polyclonal anti-STAT1, 3, or 5, or
0.5 
 
m
 
g of monoclonal anti-STAT6, or antiphosphoserine, antiphospho-
threonine, and antiphosphotyrosine. After 30 min at 4
 
8
 
C, the reactions
were further processed as described above.
The synthetic, double-stranded oligonucleotides used as probes or
competitors in the band-shift reactions were as follows (only one strand is
represented, with the binding region italicized and mutations underlined):
SIE, high affinity binding site of the c-
 
fos
 
 promoter element (SIE67; [58]):
5
 
9
 
 AGCTTCA
 
TTTCCCGTAAAT
 
CCCTA 3
 
9
 
.
mutated SIEm (SIE25; [58]): 5
 
9
 
 AGCTTCA
 
GATCCCGTCATT
 
CCCTA 3
 
9
 
.
ISRE, IFN-
 
a
 
–stimulated response element from the ISG54 gene pro-
moter (11): 5
 
9
 
 AGCT
 
AGTTTCACTTTCCC
 
 3
 
9
 
.
GAS, IFN-
 
g
 
 activation site from the guanylate binding protein gene (11):
5
 
9
 
 AGCT
 
TTACTCTAA
 
TTTCCC 3
 
9
 
.
APRE, STAT3 high affinity binding site repeated twice (1): 5
 
9
 
 ATCC
 
T-
TCCGGGAATTC
 
TGATCC
 
TTCCGGGAATTC
 
TG 3
 
9
 
.
ATF, ATF-binding site of the adenovirus-2 E2aE promoter (position
 
2
 
65/
 
2
 
84) (63): 5
 
9
 
 TCGGGAAAA
 
CTACGTCA
 
TCTCCAGC 3
 
9
 
.
 
Antibodies and Immunoreactions
 
The polyclonal anti-STAT1 (directed against residues 688–710), anti-
STAT3 (against residues 750–769), anti-STAT5 (against residues 5–24),
and anti-ERK2 (against residues 345–358) antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA); the monoclonal anti-
STAT3 (against residues 1–172) and anti-STAT6 antibodies (against resi-
dues 1–272) were provided by Transduction Laboratories (Lexington,
KY); the antiphosphoserine, antiphosphothreonine, and antiphosphoty-
rosine antibodies used in the band-shift assays were from Sigma Chemical
Co. The antiphosphotyrosine antibody used in immunoprecipitation
experiments (supernatant of the 4G10 hybridoma) was a gift from D.
Morrison. D.K. Morrison (National Cancer Institute, Frederick Cancer
Research and Development Center, Frederick, MD).
Total cell extracts (100 
 
m
 
g) were immunoprecipitated with 100 
 
m
 
l of the
4G10 antiphosphotyrosine antibody in the presence of protein A–Seph-
arose beads (Pharmacia Fine Chemicals, Piscataway, NJ) for 2 h at 4
 
8
 
C.
The beads were washed twice in TBStg buffer (20 mM Tris-HCl, pH 7.4,
125 mM NaCl, 1% Tween 20, 10% glycerol) and were resuspended in pro-
tein gel loading buffer.
About 20 
 
m
 
g of nuclear or cytosolic extracts from ES cells were electro-
phoresed on 10% acrylamide/SDS gels. Proteins were transferred onto ni-
trocellulose membranes and incubated with specific antibodies as recom-
mended by the manufacturers. Protein–antibody complexes were visualized
by an enhanced chemiluminescence detection system (Amersham Corp.,
Arlington Heights, IL).
 
In Vitro Kinase Assay
 
About 150 
 
m
 
g of nuclear or cytosolic extracts were immunoprecipitated
with 0.8 
 
m
 
g of the anti-ERK2 antibody in the presence of protein A-Seph-
arose beads (Pharmacia Fine Chemicals) for 2 h at 4
 
8
 
C. The beads were
washed twice in TBStg buffer (20 mM Tris-HCl, pH 7.4, 127 mM NaCl,
1% Tween 20, 10% glycerol), once in kinase buffer (20 mM Hepes, pH
7.4, 5 mM EGTA, 10 mM MgCl
 
2
 
, 10 mM 
 
b
 
-glycerol-phosphate, 10% glyc-
erol), and finally resuspended in 20 
 
m
 
l of kinase buffer supplemented with
20 
 
m
 
M ATP, 1 
 
m
 
Ci[
 
32
 
P]
 
g
 
-ATP, and 20 
 
m
 
g myelin basic protein (Sigma
Chemical Co.). After incubation for 30 min at 30
 
8
 
C, the reactions were
stopped in SDS sample buffer, and electrophoresed on a 10% acrylamide/
SDS gel, and processed for autoradiography. 
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Expression Vectors
 
Synthetic oligonucleotides corresponding to the high affinity wild-type
(SIE67) or mutated (SIE25) SIF-binding sites (58) were trimerized and in-
serted into the SalI site of the pBLCAT5 vector (3), upstream of the mini-
mal thymidine kinase (TK) promoter, generating the (SIE)
 
3
 
-TK and
(SIEm)
 
3
 
-TK CAT reporter vectors, respectively.
The c-Fos CAT vector bearing the human c-
 
fos
 
 promoter sequences
between positions 
 
2
 
711 and 
 
1
 
42 has been described previously (FC3 re-
combinant [46]).
The pEF-BOS and pCAGGS-Neo series of STAT3 recombinants have
been described previously (38): pEF-BOS HA-STAT3 and pCAGGS-
Neo-HA-STAT3 encode the hemagglutinin (HA)-tagged wild-type mu-
rine STAT3 protein; pEF-BOS HA-STAT3F and pCAGGS-Neo-HA-
STAT3F encode a mutant version of STAT3 in which residue Y705 has
been replaced by a phenylalanine (F); pEF-BOS HA-STAT3D encodes a
STAT3 mutant in which residues E434 and E435 of the DNA-binding do-
main have been changed to aspartates (D).
 
Transfection Assay
 
ES cells, plated the day before in the presence or absence of LIF, were
transfected by calcium phosphate coprecipitation (8) with 2 or 5 
 
m
 
g of re-
combinant DNA vectors adjusted to 20 
 
m
 
g/9-cm petri plate, with the pro-
moterless pBLCAT6 plasmid (3) used as carrier. 20 h after transfection,
the cells were washed once with PBS, and fresh medium, with or without
LIF, was added. The day after, the cells were harvested and extracts pre-
pared in buffer A (15 mM Tris-HCl, pH 8, 60 mM KCl, 15 mM NaCl, 2
mM EDTA, 0.15 mM spermine, 1 mM DTT, and 1 mM Pefabloc). Ali-
quots, normalized by protein concentration, were assayed for CAT activ-
ity as described (19). The percentage of chloramphenicol acetylation was
determined from at least three independent experiments and was quanti-
tated with a Bioimaging analyzer (Fuji Photo Film Co., Tokyo, Japan).
 
Selection of Stably Transformed Cells
 
To establish stable ES cell clones that produce the wild-type STAT3 or
mutated STAT3F proteins, ES cells, maintained on feeder cells in LIF-
containing medium, were transfected with the pCAGGS-Neo-HA-STAT3
and pCAGGS-Neo-HA-STAT3F vectors (38). After 10 d of selection, in
the presence of 400 
 
m
 
g/ml of G418, individual clones were recovered and
plated on fresh feeder cells in LIF-containing medium. The medium was
changed every other day, and cells were divided every 4 d. Morphological
differentiation of the clones overexpressing STAT3F becomes apparent
after the third passage of the clones (i.e., 
 
z
 
4 wk after transfection).
 
Results
 
A LIF-dependent DNA-binding Activity is Present in 
ES Cells
 
To identify LIF-regulated DNA-binding activities, nuclear
lysates prepared from ES cell cultures that were constantly
maintained in the presence of LIF or from which LIF was
withdrawn for 12 h were used in band-shift experiments on
selected protein-binding sites (Fig. 1). Among the five
probes chosen, four corresponded to STAT-binding sites
(SIE, ISRE, GAS, and APRE), and one (ATF) was unre-
lated (11, 63). A major LIF-dependent DNA-binding ac-
tivity was detected on the SIE probe, as revealed by spe-
cific complex formation in LIF-treated ES cell extracts
(Fig. 1, lane 
 
2
 
) compared to extracts from LIF-withdrawn
cells (Fig. 1, lane 
 
4
 
). By contrast, the specific complexes
detected with the other probes were not affected by the
LIF treatment. This result indicates that LIF mediates the
binding of specific proteins to the SIE element in ES cells.
 
The DNA-binding Activity of the
LIF-regulated Complex May Be Involved in the
Control of Cell Proliferation
 
LIF plays a key role in the maintenance of the pluripoten-
tial phenotype and active proliferation of ES cells (6, 21).
We wondered whether induction of the LIF-dependent
DNA-binding activity is linked to the proliferative func-
tion mediated by LIF in these cells. If the DNA-binding
activity drops as a result of early differentiation commit-
ment after a 2–3 d LIF withdrawal, no recovery of specific
complex formation would occur after LIF reinduction. By
contrast, if this binding activity is involved in cell growth
control, it should be reinduced by short treatments with
LIF in cells that can still proliferate. To test this possibility,
we used the LIF-regulated SIE- and nonregulated APRE-
binding sites as probes in band-shift experiments with nu-
clear extracts from ES cells that had been grown in the ab-
sence of LIF for increasing time periods and treated by
LIF for 10 min before cell harvesting. As shown in Fig. 2,
specific DNA-binding activity on the SIE was recovered
after a 10-min LIF reinduction, following a 12-h LIF depri-
vation (Fig. 2, lane 
 
6
 
). As reflected by the intensity of the
retarded complex, the binding activity is much stronger af-
ter LIF reinduction than in cells that had been grown in
the continuous presence of LIF (Fig. 2, compare lanes 
 
2
 
and 
 
6
 
). Efficient complex reinduction also occurred 4 d af-
ter LIF withdrawal (not shown). Reinduction was much
weaker after 8 d of LIF deprivation (Fig. 2, lane 
 
10
 
), and
became undetectable after 11 d (Fig. 2, lane 
 
14
 
), a stage at
which the cell growth rate was reduced dramatically. By
contrast, no major modulation of the DNA-binding activi-
ties was detected on the APRE probe (Fig. 2, lanes 
 
15–28
 
).
Altogether, these results suggest that the DNA-binding
activity detected on the SIE probe is part of the prolifera-
tive signal mediated by LIF, and that modulators of this
activity are still present in ES cells during the first week af-
ter differentiation commitment.
Figure 1. A LIF-dependent DNA-binding activity is detected in
ES cells. Nuclear extracts from ES cells constantly maintained in
the presence of LIF (1) or grown in the absence of LIF for 12 h
(2) were used in standard band-shift assays with the 59 end-
labeled SIE, ISRE, GAS, APRE, or ATF probes as indicated
(see Materials and Methods). A 100-fold molar excess of each
corresponding unlabeled wild-type oligonucleotide (wt) or of the
mutated SIE oligonucleotide (m) was added as competitor to the
binding reactions. F, the unbound probe. The arrowhead in lane 2
points to the LIF-regulated complex. 
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The Steady-state Level of STAT Proteins in ES Cells Is 
Not Dependent on LIF Treatment
 
We next examined the presence of STAT proteins in ES
cells and determined their overall levels as a function of
LIF treatment. To this end, nuclear lysates from cells that
had been maintained in the presence of LIF or cultivated
in its absence for increasing time periods were analyzed by
immunoblotting with specific STAT antibodies. As seen in
Fig. 3, STAT1, 3, 5, and 6 were readily detected in ES cells,
and their respective amounts were not affected signifi-
cantly by LIF withdrawal: the level of each of these pro-
teins remained unchanged, even after growing the ES cells
in the absence of LIF for 3 d, a time at which morphologi-
cal differentiation of ES cells became apparent.
 
The LIF-regulated Complex Comprises a 
Phosphoprotein Immunologically Related to STAT3
 
To determine which member of the STAT family gener-
ates the LIF-regulated complex detected in ES cells, we
examined the effect of antibodies specifically directed
against different STAT proteins. As shown in Fig. 4, only
the STAT3 antibody produced a clear supershift of the
LIF-dependent complex with the SIE probe (Fig. 4, lane
 
4
 
), whereas antibodies to STAT1 (Fig. 4, lane 
 
3
 
), STAT5
(Fig. 4, lane 
 
5
 
), or STAT6 (not shown) had no effect on
this complex. Interestingly, the LIF-regulated complex
was supershifted only by an antibody directed against the
COOH-terminal part (residues 750–769) of STAT3
 
a
 
 (Fig.
4, lane 
 
4
 
), but not by an antibody directed against residues
628–640 (not shown) that recognizes both STAT3
 
a
 
 and
STAT3
 
b
 
 (48). It is possible therefore that this latter
epitope is hidden within the folded molecule or by associa-
tion with yet unknown proteins. Similar experiments with
the APRE probe revealed that none of these antibodies
could supershift any of the specific retarded complexes
(not shown), further stressing the specificity of the LIF-
dependent complex assembled on the SIE site.
When nuclear lysates were prepared in the absence of
phosphatase inhibitors (like sodium vanadate or sodium
fluoride), formation of the LIF-dependent complex was
impaired (not shown), suggesting that phosphorylation of
this complex was important for its DNA-binding activity.
To examine this possibility in further detail, we tested the
effect of antibodies directed against phosphorylated amino
acids on specific complex formation. Antibodies against
phosphotyrosine (Fig. 4, lane 
 
6
 
) and phosphoserine (Fig. 4,
lane 
 
7
 
) supershifted the LIF-specific complex, whereas an-
tiphosphothreonine antibodies had no effect (Fig. 4, lane
 
8
 
). In agreement with the earlier finding that STAT pro-
teins are rapidly phosphorylated on serine and tyrosine
Figure 2. The LIF-depen-
dent DNA-binding complex
is reinducible by LIF up to 8 d
without LIF. Nuclear ex-
tracts were prepared from
ES cells that were main-
tained with LIF or without
LIF for 12 h and 8 or 11 d
(212h,  28d, or 211d, re-
spectively) and reinduced
with LIF for 10 min where in-
dicated. Standard band-shift
assays were run with the 59
end-labeled SIE or APRE
probes in the presence of
wild-type (wt) or mutant (m)
SIE competitors, as indicated.
The arrowheads refer to the
LIF-regulated complexes.
Figure 3. STAT protein expression remains constant in the pres-
ence and absence of LIF. Nuclear extracts were prepared from
ES cell cultures that were maintained in the presence of LIF (1)
or those from which LIF was removed for 12, 48, or 72 h, as indi-
cated. Immunoblot analyses were performed with specific anti-
STAT antibodies, as described in Materials and Methods.Boeuf et al. LIF–mediated Regulation of STAT3 1211
residues after cytokine or growth factor treatment (50, 60,
64), this result strongly suggests that the STAT3-contain-
ing complex is phosphorylated on these residues within
the LIF-regulated complex.
STAT3 Is Present in Tyrosine-phosphorylated 
Complexes Only upon LIF Treatment
To determine if STAT3 is present in a tyrosine-phosphor-
ylated complex in LIF-treated ES cells, we have per-
formed immunoprecipitation experiments with the 4G10
antiphosphotyrosine antibody. Western blot analysis of
the tyrosine-phosphorylated immune complexes is shown
in Fig. 5. STAT3 protein is detected in tyrosine-phosphor-
ylated complexes only in LIF-treated cells, with a higher
pool of STAT3 protein in LIF-reinduced cells, compared
to cells continuously maintained in the presence of LIF
(Fig. 5, compare lanes 4 and 6). Phosphorylation of the
STAT3 complex correlates with its DNA-binding activity
(Fig. 2, compare lanes 2, 4, and 6).
Protein Kinase Inhibitors Impair the
DNA-binding of the LIF-dependent STAT3 Complex 
and Alter Cell Morphology
We next examined the dependence of the LIF-induced
complex on protein phosphorylation. ES cells, maintained
in the presence of LIF, were treated for 20 h with specific
tyrosine kinase inhibitors (Genistein and Herbimycin A)
or with a more general protein kinase inhibitor (Stauro-
sporine; 2, 32, 47 and references therein). As shown in Fig.
6 A, Genistein treatment did not prevent specific complex
formation (Fig. 6 A, compare lanes 2 and 4). Control ex-
periments have been performed in the epidermoid A 431
cell line treated with EGF, in which the formation of the
STAT1/STAT3 heterodimeric complex is completely
abolished by Genistein, as expected from earlier studies
(17, 45; data not shown). By contrast, treatment of the
cells with Herbymicin A completely abolished formation
of the STAT3-containing complex (Fig. 6 A, compare
lanes  14 and 16). In the presence of Staurosporine, forma-
tion of the LIF-dependent complex was also severely im-
paired (Fig. 6 A, lane 6). No detectable effect was ob-
served on the APRE-specific complexes in the presence of
either inhibitor (Fig. 6 A, lanes 7–12 and 17–20). Together
with the effect of the antibodies against specific phosphor-
ylated amino acids, these results indicate that phosphory-
lation of the STAT3-containing complex on serine and ty-
rosine residues is essential for its competence to bind DNA.
We have also observed that ES cells treated with Stau-
rosporine and Herbimycin A undergo striking changes in
their morphology reminiscent of alterations that occur
during cell differentiation (see Fig. 6 B). In the presence of
these inhibitors, cells no longer grow as clumps character-
istic of undifferentiated cells, but become flattened in the
presence of Herbimycin A and are completely individual-
ized in the presence of Staurosporine. This result suggests
that impairment of the formation of the STAT3-depen-
dent complex may lead to morphological cell differentia-
tion.
Figure 4. The LIF-dependent complex contains a STAT3-related
protein and is phosphorylated both on tyrosine and serine resi-
dues. Nuclear extracts from ES cells maintained in the presence
of LIF were preincubated for 30 min with 1 mg of anti-STAT1,
anti-STAT3, or anti-STAT5 (a stat 1, a stat 3, or a stat 5, respec-
tively), or with 0.5 mg of the antiphosphotyrosine, antiphospho-
serine, or antiphosphothreonine (a pY, a pS, or a pT, respec-
tively), as indicated. Standard band-shift assays were then
performed with the 59 end-labeled SIE probe and wild-type (wt)
or mutant (m) SIE competitors, as indicated. The arrowhead
points to the position of the LIF-dependent complex.
Figure 5. STAT3 is present in tyrosine-phosphorylated com-
plexes only upon LIF treatment. Whole-cell extracts were pre-
pared from ES cells that were maintained with LIF (1) or with-
out LIF for 12 h (212h) and reinduced or not with LIF for 10
min, as indicated. The extracts (20 mg) were loaded, either di-
rectly (Lysate) or after immunoprecipitation with the antiphos-
photyrosine antibody [IP(a pY)], on SDS-polyacrylamide gels,
and were analyzed with the anti-STAT3 antibody. Arrows point
to bands corresponding to STAT3. The heavy (H) and light (L)
chains of the anti-pY Igs are also revealed.The Journal of Cell Biology, Volume 138, 1997 1212
The ERK2 Serine/Threonine Kinase Activity Is Induced 
by LIF
The ERK2 serine/threonine kinase has recently been shown
to interact with STAT1 in IFN-a/b–induced cells (13). Sim-
ilarly, serine/threonine kinases of this family play critical
roles during the differentiation of PC12 cells (35). In addi-
tion, it has been shown that LIF stimulates ERK2 activity
in 3T3 fibroblasts (49, 61). We tested the possibility that
ERK2 is associated with STAT3 in ES cells, and deter-
mined the activity of this particular kinase as a function of
LIF treatment. Nuclear and cytoplasmic extracts from ES
cells cultivated in the presence or absence of LIF for 12 h
and reinduced by LIF for 10 min were immunoprecipi-
tated with an anti-ERK2 antibody. As revealed by immu-
noblot analysis (Fig. 7), the level of ERK2 remained con-
stant in ES cells whether they were treated or not with
LIF. Under our immunoprecipitation conditions, neither
STAT1 nor STAT3 were found to be associated with the
ERK2 kinase in the different cell lysates (not shown). Sim-
ilarly, ERK2 could not be detected in STAT3 immunopre-
cipitates (not shown), indicating that no stable interactions
exist between these proteins in ES cells and, if they do exist,
that such interactions occur only transiently. The in vitro
kinase activity, as measured by phosphorylation of the ex-
ogenous MBP substrate, was not significantly affected by
LIF withdrawal (Fig. 7, lanes 1 and 2). When these cells
were reinduced by LIF for 10 min before extract prepara-
tion, however, a strong increase in ERK2 kinase activity
was reproducibly observed. Very similar results were ob-
tained whether ERK2 was analyzed in nuclear (Fig. 7) or
in cytoplasmic (not shown) extracts. These results indicate
that ERK2 is modulated in a LIF-dependent manner in ES
cells without altering its subcellular distribution. In agree-
ment with the more efficient complex formation after LIF
reinduction after 12 h (see Fig. 2, lane 6) they also suggest
that ERK2 or a closely related serine/threonine kinase may
be part of the primary signal mediated by LIF in these cells.
Multimerized SIE Elements Confer LIF
Responsive Transcriptional Activity to Chimeric 
Promoters in ES Cells
Multimerized STAT-binding elements have previously
been shown to behave as cytokine-inducible elements
when inserted upstream of a minimal promoter (33). We
examined whether formation of the LIF-dependent com-
plex on the SIE element could be correlated, in the con-
text of ES cells, with the transcriptional activation of a re-
porter gene harboring this element.
Figure 6. LIF-dependent complex is sensitive to Staurosporine
and Herbimycin A. (A) The 59 end-labeled SIE or APRE probes
were used in the presence of wild-type (wt) or mutant (m) SIE
competitors in standard band-shift assays with nuclear extracts
derived from ES cells maintained with LIF and treated for 20 h
with 27 mg/ml of Genistein (G), 100 nM Staurosporine (S), or 1
mg/ml Herbimycin A (H) when indicated. Arrowheads point to
the LIF-regulated complexes. (B) Phase contrast micrographs of
ES cells treated or not (control) with the different kinase inhibi-
tors. Bar, 40 mm.
Figure 7. An ERK2-related MAP kinase is activated in ES cells
reinduced by LIF. Nuclear extracts from ES cells maintained with
LIF or without LIF for 12 h (212h) and reinduced by LIF for 10
min, as indicated, were immunoprecipitated with the anti-ERK2
antibody, as described in Materials and Methods. Two thirds of
the reaction were assayed in an in vitro kinase assay using MBP
as an exogenous substrate (top). The remaining third of the reac-
tion was analyzed by immunoblot with the anti-ERK2 antibody
(bottom). The asterisk refers to the heavy chains of the Igs. Num-
bers on the right-hand side indicate the position of protein size
markers (kD).Boeuf et al. LIF–mediated Regulation of STAT3 1213
To this end, ES cells cultivated in the absence or pres-
ence of LIF were transfected with chloramphenicol acetyl
transferase (CAT) reporter plasmids differing in their pro-
moter elements. The results of a typical CAT analysis is
shown in Fig. 8 A, along with the mean values of similar in-
dependent experiments (Fig. 8 B). It clearly appears that
the high-affinity SIE element, when linked as a trimer to
the minimal TK promoter [(SIE)3-TK], confers LIF re-
sponsiveness to the CAT reporter. The specificity of these
results was further substantiated by the observation that,
under the same conditions, the TK promoter, whether
alone or fused to a mutated SIE element [(SIEm)3-TK],
showed no or very low LIF-responsiveness. Interestingly,
insertion of a single SIE element in front of the TK pro-
moter did not generate a LIF-responsive construct (not
shown, [33]), while in the context of the natural c-fos pro-
moter, a single low-affinity SIE element (present at posi-
tion 2346), was sufficient to confer LIF responsiveness to
a c-Fos CAT reporter (Fig. 8 B). This observation stresses
the importance of the relative position of the SIE element
with respect to the start site or to the surrounding pro-
moter elements. It is possible, therefore, that trimerization
of the SIE element, as in the (SIE)3-TK CAT construct,
somehow compensates for the artificial structure of this
synthetic promoter.
STAT3 Is a Key Mediator of the LIF-regulated 
Transcription in ES Cells
To further investigate the contribution of STAT3 to LIF
responsiveness, we attempted to compete for the endoge-
nous protein by overexpressing STAT3 dominant negative
mutants in ES cells. We used STAT3 vectors (STAT3F, in
which residue Y705 has been mutated to phenylalanine,
and STAT3D, in which two critical residues in the DNA-
binding domain, E434 and E435, have been changed to
alanine [24]) whose expression had previously been shown
to impair IL-6–dependent transcription and cell differenti-
Figure 8. The SIE element confers LIF responsiveness to a heter-
ologous promoter in ES cells. (A) ES cells maintained with (1)
or without (2) LIF were transfected with 2 (odd lanes) or 5 mg
(even lanes) of the CAT reporters: pBLCAT5 (referred to as
TK), (SIE)3-TK, and (SIEm)3-TK, as indicated. The results of a
typical CAT assay with corresponding quantification are pre-
sented. (B) Transfection experiments were performed as de-
scribed above, but using 5 mg of each of the indicated CAT re-
porters and including the c-Fos CAT reporter. The mean (6SD)
of four independent experiments performed with different plas-
mid preparations is plotted.
Figure 9. Dominant negative mutants of STAT3 negatively inter-
fere with LIF-dependent promoter activity. (A) ES cells maintained
with LIF were cotransfected with 5 mg of the CAT reporters
[pBLCAT5 (referred to as TK), (SIE)3-TK, and (SIEm)3-TK], to-
gether with 3 mg of the empty pEF-BOS vector (lanes 1, 5, and 9),
the pEF-BOS HA-STAT3 (lanes 2, 6, and 10), the pEF-BOS
HA-STAT3F (lanes 3, 7, and 11), or the pEF-BOS HA-STAT3D
(lanes 4, 8, and 12), as indicated. The results of a typical CAT as-
say with corresponding quantification are presented. (B) The
mean (6SD) of three independent experiments performed as de-
scribed above, with different plasmid preparations, is plotted.
Depending on the experiment, cotransfection of the (SIE)3-TK
CAT reporter with the pEF-BOS HA-STAT3 vector resulted ei-
ther in a slight stimulation or slight repression of CAT activity
compared to cotransfection with the empty pEF-BOS vector.
This variation, probably reflecting differences in recipient cell
conditions, generated artificially elevated SD values: the mislead-
ing error bar was therefore omitted on the corresponding column.The Journal of Cell Biology, Volume 138, 1997 1214
ation (38). These vectors were transfected into ES cells
maintained in the presence of LIF, together with the LIF-
responsive or nonresponsive CAT reporters. The results
of a typical CAT analysis are shown in Fig. 9 A, along with
the compiling of the results of similar independent experi-
ments (Fig. 9 B). As expected from Fig. 8, the LIF-respon-
sive (SIE)3-TK promoter exhibited the highest reporter
activity when transfected with the empty STAT vector
(Fig. 9, lane 5 and corresponding column). Coexpression
of the wild-type STAT3 protein (“3”) had no significant
effect on this reporter activity (Fig. 9, compare lanes 5 and
6 and corresponding columns), although slight variations
were observed from one experiment to the other, probably
reflecting fluctuations of the pool of active STAT3 in the
transfected cells. Under conditions where nearly identical
amounts of recombinant STAT3 proteins were produced
(as monitored by Western blot analysis, not shown), coex-
pression of the mutant STAT3 proteins severely repressed
the LIF-dependent reporter activity (Fig. 9, lanes 7 and 8
and corresponding columns), whereas it had virtually no
effect on basal reporter activity (Fig. 9, compare lanes 1–4
and  9–12 and corresponding columns). These results
clearly support the conclusion that STAT3 mediates LIF-
dependent transcriptional activation in ES cells.
Stable Expression of a Dominant-Negative STAT3 
Mutant Induces ES Cell Differentiation in the Presence 
of LIF
If, as suggested by the experiments described above,
STAT3 is an essential intermediate in LIF signaling in ES
cells, the expression of a dominant-negative allele that
blocks the effect of the endogenous STAT3 should impair
the action of LIF and thereby allow the cells to differenti-
ate. To examine this possibility, we established ES cell
lines that were stably transformed with vectors expressing
either the wild-type STAT3 sequence or the dominant-
negative mutant STAT3F. Both constructs generated neo-
mycin-resistant clones with similar efficiencies. 10 clones
of each type were picked, and STAT3 and STAT3F ex-
pression levels were examined by Western blot analysis:
all clones overexpressed the STAT3 proteins compared to
untransfected cells. The cells overexpressing STAT3F,
however, had a much greater propensity to differentiate
than the STAT3 transformants, although they were grown
under identical conditions, on feeder cells and in the pres-
ence of LIF. Specifically, 1 mo after the transfection and
selection procedure, all STAT3F-transformed ES cells had
undergone morphological differentiation, whereas ,5%
of the STAT3-transformed cells exhibited an altered mor-
phology. As expected, the clones exhibiting the highest
levels of STAT3F expression were the first to differenti-
ate. A typical analysis with two clones, one of each type, is
shown in Fig. 10. These results clearly indicate that the
STAT3 protein is chiefly involved in the keeping of ES cell
pluripotentiality.
Discussion
The LIF cytokine plays a key role in the maintenance of
the pluripotential phenotype and proliferation of ES
cells in vitro. We have investigated how the LIF regulates
the specific binding and transcriptional properties of a
STAT3-based complex in ES cells. We present evidence
suggesting that phosphorylation of this complex is the pri-
mary response of LIF-induced cell proliferation, and we
demonstrate that STAT3 is a critical component of LIF-
dependent transcription in ES cells.
In an earlier study, Hocke et al. (23) detected a LIF-
inducible DNA-binding activity on the IL-6 response ele-
ment of the rat a2-macroglobulin (a2 M) gene and showed
that STAT3 is part of this complex. These authors also
demonstrated that the downregulation of the LIF receptor
in LIF-deprived cells correlates with the loss of the LIF-
dependent complex. Similarly, we show that the DNA-bind-
ing activity detected on the SIE probe dropped rapidly af-
ter LIF deprivation. We further extend this observation by
showing that regulators which activate STAT3 DNA-bind-
ing capacity remain reinducible by the LIF within the first
week of LIF deprivation. The extent of reinduction de-
creases progressively, however, together with the slacken-
ing of cell growth.
Inhibition of STAT3 Phosphorylation
Correlates with the Loss of DNA-binding Activity
and with Morphological Alterations of ES Cells
We have shown that the level of the STAT3 protein re-
mains constant in ES cells whether or not they were
treated with LIF, but that tyrosine-phosphorylated com-
plexes containing STAT3 are detected only in the pres-
ence of LIF. Our data demonstrate that DNA-binding ac-
tivity correlates with phosphorylation on tyrosine and with
the activation of the ERK2 serine/threonine kinase, whose
activity is dependent on tyrosine phosphorylation (39, 57).
Two lines of evidence suggest that ERK kinases may phos-
phorylate STAT3 despite the fact that we could not visual-
ize any interaction between STAT3 and ERK2 (not shown):
(a) the sensitivity of the STAT3-containing complex to
Herbimycin A, a potent inhibitor of tyrosine kinases that
Figure 10. Stable expression of STAT3F dominant negative mu-
tant induces ES cell differentiation. Phase contrast micrographs
of Neomycin-resistant ES cell clones stably expressing the wild-
type STAT3 (A) or the dominant negative STAT3F mutant (B).
The selected clones were grown on feeder layers of mouse em-
bryo fibroblasts (visible in A between the clumps of undifferenti-
ated ES cells) and continuously maintained in the presence of
LIF. (C) Western blot analysis of equivalent amounts of whole-
cell extracts of STAT3- (lane 1) or STAT3F-transformed cells
(lane 2), or untransformed ES cells (lane 3). The arrow points to
the specific signal obtained with the monoclonal anti-STAT3 an-
tibody. Bar, 100 mm.Boeuf et al. LIF–mediated Regulation of STAT3 1215
alters MAP kinase function in vivo; and (b) the finding
that Ras, a known MAP kinase inducer, is involved in LIF
signaling in ES cells (15, 47, 61). We did not detect any sig-
nificant alteration in the relative nuclear and cytoplasmic
distribution of ERK2 after LIF treatment. This is in con-
trast to PC12 cells, in which sustained MAP kinase activa-
tion by NGF leads to the nuclear translocation of the ki-
nase and to cell differentiation, whereas upon short-lived
activation by EGF, which triggers cell proliferation, the ki-
nase remains essentially cytosolic (35). The differentiation
program, which settles in ES cells in the absence of LIF,
may therefore not require relocation of ERK2 in different
cell compartments. On the other hand, the possibility that
a distinct but related protein kinase(s) is implicated in ES
cells cannot be formally excluded.
The tyrosine kinases of the Jak and Src families involved
in gp130-dependent signaling are also potential candidates
for STAT3 phosphorylation (14, 34, 52). In fact, members
of these families of tyrosine kinases play essential roles in
ES cells: clones of ES cells that overexpress the oncogenic
form of the v-Src protein exhibit LIF-independent growth
(4); the Hck tyrosine kinase is activated upon LIF signal-
ing in ES cells, and LIF requirement decreases in cells that
constitutively express an activated form of Hck (14); the
activity of JAK1 and JAK2 tyrosine kinases is induced
upon LIF treatment in ES cells, and it has been suggested
that Hck and Jak kinases induce two alternative LIF-
dependent pathways (15). Our experiments suggest that
STAT3 is probably a common target of both pathways,
with MAP kinases playing an essential role during the LIF
reinduction process.
Interestingly, in cells treated with Staurosporine, a gen-
eral kinase inhibitor known to block cells in both G1 and
G2-M phases (32), formation of the STAT3-dependent
complex is impaired, and the cells undergo morphological
changes that mimic cell differentiation. Similarly, in cells
treated with Herbimycin A, a drug that blocks mainly the
activity of cytoplasmic tyrosine kinases (47), there is also a
correlation between the disappearance of the STAT3-con-
taining complex and an alteration in cell morphology.
These results suggest that LIF-dependent STAT3 activa-
tion is linked to the maintenance of ES cell pluripotential-
ity, a conclusion that is further substantiated by the ob-
servation that overexpression of the STAT3F dominant
negative mutant in ES cells triggers their morphological
differentiation in the presence of LIF.
The STAT3 Transcription Factor Is a Key
LIF-signaling Intermediate
STAT3 is induced by IL-6 and LIF during myeloid cell dif-
ferentiation. The impairment of STAT3 signaling by ex-
pression of dominant-negative mutants of STAT3 (STAT3F
and STAT3D) leads to transcriptional repression and af-
fects the differentiation program in these cells (37, 38).
These mutants prevent proper tyrosine phosphorylation of
the endogenous STAT3 protein, probably by blocking the
wild-type protein’s access to the gp130 receptor (37, 38).
Repression of IL-6–dependent transcription has also been
reported in HepG2 cells expressing the STAT3F mutant
(30). We show that STAT3F and, to a lesser extent,
STAT3D repress LIF-dependent transcription in ES cells.
These data, together with results obtained with the kinase
inhibitors, clearly emphasize the critical contribution of
the tyrosine Y705 residue of STAT3 (a residue that is
phosphorylated upon STAT3 activation) to STAT3 tran-
scriptional efficiency.
Differential Behavior of STAT3 Recognition Sites
The APRE-binding site is a STAT3 recognition element that
has originally been used to purify STAT3a from the rat
liver (1). In our study, the APRE-specific complexes are
not modulated by LIF, and their formation is not altered
in lysates derived from cells treated with kinase inhibitors.
In addition, as opposed to the (SIE)3-TK-CAT and of the
c-fos–CAT reporter activities, the APRE-TK-CAT re-
porter activity was not responsive to LIF treatment (not
shown). Interestingly, these APRE-specific complexes
were not supershifted by an anti-STAT3 antibody directed
against the COOH-terminal part of STAT3a (our unpub-
lished observation). It is therefore possible that in ES cell
extracts, these complexes contain STAT3b, a natural trun-
cated form of STAT3 lacking the COOH-terminal part of
STAT3a. In IL-6–treated cells, this particular form of
STAT3 behaves as a constitutive transcription factor (48).
It is therefore tempting to speculate that, in ES cells, a
constitutive STAT3b-containing complex interacts with
the APRE site, while a LIF-inducible STAT3a activity
binds to the SIE site.
In conclusion, together with earlier findings (23, 37, 38),
this report demonstrates that STAT3 is a LIF-dependent
transcription factor that exerts opposite effects in ES cells
and in the M1 myeloid cells. It is tempting to speculate
that STAT3 is a common component of larger complexes
that may mediate variable responses. The characterization
of the partners of this common effector will ultimately
help us to better understand the control mechanisms that
are involved in each of these specific responses.
Together with the essential contribution of STAT3 in
liver regeneration (10) and in antiapoptotis (18), the re-
cent observation that STAT3 genetic disruption leads to
embryonic lethality (55) stresses the essential function of
STAT3 in early cell differentiation programs. The estab-
lishment of stable ES cell lines in which the expression of
STAT3 dominant negative mutants is inducible should
help us to further analyze the contribution of STAT3 to
the maintenance of ES cell pluripotentiality.
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